drugset
drugset / Trial / NCT04812691

CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma

NCT04812691 ↗

Phase 1 Completed 12 enrolled Shanghai Ming Ju Biotechnology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I, open-label, single-arm, multicenter study to assess the safety and efficacy of JWCAR029 in adult primary refractory DLBCL subjects in China

Timeline

Start
2020-07-10
Primary completion
2021-06-30
Completion
2023-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Relmacabtagene Autoleucel Cell therapy 1e+08 cells Intravenous

Indications

diffuse large B-cell lymphoma